Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Purchases 33,357 Shares

Abrdn Life Sciences Investors (NYSE:HQLGet Free Report) major shareholder Saba Capital Management, L.P. acquired 33,357 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was purchased at an average price of $13.50 per share, for a total transaction of $450,319.50. Following the acquisition, the insider now directly owns 3,354,025 shares in the company, valued at $45,279,337.50. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

  • On Thursday, May 30th, Saba Capital Management, L.P. purchased 669 shares of Abrdn Life Sciences Investors stock. The stock was acquired at an average price of $13.05 per share, for a total transaction of $8,730.45.
  • On Tuesday, May 28th, Saba Capital Management, L.P. acquired 8,714 shares of Abrdn Life Sciences Investors stock. The shares were acquired at an average price of $13.38 per share, with a total value of $116,593.32.
  • On Thursday, May 23rd, Saba Capital Management, L.P. bought 1,303 shares of Abrdn Life Sciences Investors stock. The stock was acquired at an average cost of $13.50 per share, for a total transaction of $17,590.50.
  • On Wednesday, May 15th, Saba Capital Management, L.P. purchased 34,755 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average cost of $14.19 per share, with a total value of $493,173.45.
  • On Friday, May 10th, Saba Capital Management, L.P. purchased 57,862 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $13.86 per share, with a total value of $801,967.32.
  • On Wednesday, May 8th, Saba Capital Management, L.P. acquired 10,986 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average price of $13.70 per share, for a total transaction of $150,508.20.
  • On Monday, May 6th, Saba Capital Management, L.P. acquired 10,713 shares of Abrdn Life Sciences Investors stock. The shares were bought at an average cost of $13.62 per share, with a total value of $145,911.06.
  • On Thursday, May 2nd, Saba Capital Management, L.P. bought 26,274 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $13.46 per share, for a total transaction of $353,648.04.
  • On Tuesday, April 30th, Saba Capital Management, L.P. purchased 16,573 shares of Abrdn Life Sciences Investors stock. The stock was purchased at an average price of $13.13 per share, with a total value of $217,603.49.
  • On Friday, April 26th, Saba Capital Management, L.P. acquired 120,304 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average price of $13.00 per share, for a total transaction of $1,563,952.00.

Abrdn Life Sciences Investors Trading Down 0.4 %

Shares of NYSE HQL opened at $13.75 on Friday. Abrdn Life Sciences Investors has a twelve month low of $11.34 and a twelve month high of $14.37. The business has a 50 day simple moving average of $13.41 and a 200-day simple moving average of $13.43.

Abrdn Life Sciences Investors Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Shareholders of record on Thursday, May 23rd will be paid a dividend of $0.48 per share. This is a positive change from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Wednesday, May 22nd. This represents a $1.92 annualized dividend and a yield of 13.96%.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Future Financial Wealth Managment LLC bought a new stake in shares of Abrdn Life Sciences Investors during the 1st quarter valued at about $27,000. Matisse Capital acquired a new position in Abrdn Life Sciences Investors in the fourth quarter valued at approximately $135,000. Blue Bell Private Wealth Management LLC grew its holdings in shares of Abrdn Life Sciences Investors by 60.4% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company’s stock valued at $136,000 after purchasing an additional 3,811 shares during the last quarter. Eudaimonia Partners LLC acquired a new stake in shares of Abrdn Life Sciences Investors during the 1st quarter worth approximately $142,000. Finally, International Assets Investment Management LLC lifted its holdings in shares of Abrdn Life Sciences Investors by 3,424.5% in the 4th quarter. International Assets Investment Management LLC now owns 11,067 shares of the company’s stock worth $149,000 after purchasing an additional 10,753 shares during the last quarter. 32.21% of the stock is currently owned by institutional investors.

About Abrdn Life Sciences Investors

(Get Free Report)

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.

See Also

Insider Buying and Selling by Quarter for Abrdn Life Sciences Investors (NYSE:HQL)

Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.